Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-2536. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 15/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | TAF1 | P21675 | 5/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | CLK2 | P49760 | 3/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-2536 SCHEMBL614114 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL372489 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL16984416 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL29644993 | 0.99 | BRD4 (0.99) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL13227794 | 0.96 | BRD4 (0.92) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL24851804 | 0.96 | PLK1 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL4515444 | 0.95 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972068 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972069 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL376236 | 0.94 | PLK1 (0.89) | BRD4PLK1PLK3ALKTAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705491-A2 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | Mirus Bio LLC (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024229131-A9 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | MIRUS BIO LLC (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024229131-A2 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | MIRUS BIO LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4705491-A2 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | Mirus Bio LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025051878-A1 | TREATMENT OF INFLAMMATORY DISEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024229131-A9 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | MIRUS BIO LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4461370-A2 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA | Celgene Corporation (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024229131-A2 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | MIRUS BIO LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023059582-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-115607552-A | Combined use of a substituted 4-aminoisoindoline-1, 3-dione compound and a second active agent | 新基公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| CN-114404596-A | Antiproliferative compounds and second agents for the treatment of multiple myeloma | 细胞基因公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-105682658-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PLK1 3968/4885BRD4 651/4885PLK3 3484/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | PLK1 283/4885BRD4 3891/4885PLK3 413/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PLK1 3968/4885BRD4 651/4885PLK3 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.